LabGenius

EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉 The round was led by M Ventures with participation from new investors Octopus Ventures, LG Corp. and Recode Ventures alongside existing investors Atomico, Kindred Capital VC, Lux Capital and Obvious Ventures. The proceeds from the round will enable us to further advance our ML-driven antibody discovery platform and progress a pipeline of multispecific antibodies for the treatment of solid tumours towards the clinic. As part of this fundraise, we welcome Oliver Hardick (M Ventures) and Oliver Sims (Octopus Ventures) to the Board. They will serve alongside current Board members Edwin Moses (Chairman), Irina Elena Haivas (Atomico) and Leila Rastegar Zegna (Kindred). 🗞️ For more details on the round, check out the press release here - https://lnkd.in/erQrPsTE 💡Our CEO, James Field, shares his personal perspective on what this financing means for LabGenius here - https://lnkd.in/eKZen4rm

We're looking for a Staff Software Engineer to join our fantastic team at LabGenius! ✨ This is a senior position in the software team, and requires a blend of technical expertise, leadership and mentoring skills, and a deep understanding of the biotech industry. https://lnkd.in/eU4hH9vu

Attending The JPM Healthcare Conference next week? LabGenius’ CEO, Dr. James Field, and CBO, Dr. Hannah Seitz, will be there to discuss how our automated discovery platform —EVA™— enables the rapid identification and co-optimisation of complex multispecific antibodies across multiple key properties, including killing selectivity, potency and developability. To learn more about LabGenius' cutting-edge platform and therapeutic pipeline, please reach out to Hannah or James. Or email us at partnerships@labgeni.us

We’re excited to announce that Dr. Hannah Seitz has joined the LabGenius Team as Chief Business Officer. Hannah, who was previously Evotec’s VP Global Business Development, will lead LabGenius’ business development activities. “We’re delighted that Hannah has joined the team,” said Dr. James Field, CEO of LabGenius. “Her extensive experience in sourcing and executing deals, combined with our proven ability to discover high-performing molecules with non-intuitive designs, will be instrumental in the success of our partnerships.” Read more about the appointment here: https://lnkd.in/eHrCWi-r

Attending The BioLogic Summit next week? Join our Head of Data Science and Machine Learning, Dr. Winston Haynes, for his presentation describing how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target, off-tumour toxicity. Find out more here: https://lnkd.in/eKBxRavf

Did you miss our presentation at #PEGSEurope? Watch the video below to hear James Field describe how LabGenius' unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target off-tumour toxicity. Interested in learning more? Get in touch via: partnerships@labgeni.us

Are you attending #PEGSEurope? Join our CEO, James Field, as he describes how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target off-tumour toxicity. 📅 Wednesday, 6 November 2024 ⏰ 12:15 pm 📍#PEGSEurope, Spain

I am delighted to see LabGenius recognised as one of the UK's top 25 start ups to watch by Bloomberg. There's a chance I am biased...but I completely agree! Keep an eye on them as they develop better #multispecific #antibody drugs for diseases using #AI. https://lnkd.in/eBU4q_qt Also well done to ORCA Computing from Octopus Ventures deeptech portfolio. Delivering the world #photonic #quantum computing systems. And a special shoutout to Sano Genetics and Patrick Short, who i've watched build Sano over the years. Exciting to see you and the team recognised as well!

I am looking forward to speaking at #BioLogicSummit (January 13 - 16, San Diego) on our work at LabGenius using ML to optimise T-cell engagers for selective killing of tumor cells. Hope to see you there!

We're looking for an enthusiastic and skilled IT Technician to join our brilliant team! ✨ The IT Technician role is responsible for maintaining the company's IT infrastructure, providing technical support to employees, and ensuring the smooth operation of all IT-related activities. 💻 If this sounds like the opportunity for you, please apply here: https://lnkd.in/eyPERe2s